Welcome to us Thank you, joining Matt. afternoon. this everyone
and cut top low upon debt from and accretive to market, our our new Sympazan of added of new the our of Not financial of revenue profitability forecast an immediately creation weeks growth. in were improved once of unprofitable third and for The and of did business, quarter in future important XX% extend the to a in our nearly the maturity followed the were able our we diversification line. platform revenue the to incredibly our and a strategic We've capital increasing from metric, the adds results today's again that our in segment quarter now profit a we that exit source X.X%, to restructuring our of exceed cost only which X pivoted most business Assertio. periods quarterly commercial every debt towards in period of
of have new new actions positioned possible We've actions, our potentially more result we existing priorities. attracting nearly In say When business had and to base we our I'm XX% added and had and employee and key X achieved to XXXX, retaining investors. a employees we our new attractive private have X. and these tumultuous our we stock we that our As execute public job a the to third is first are development talent. other priority began today XXX% transactions with X proud in in all or set environment, over of quarter, employees retention better growth.
to successfully into priority We nonpersonal negative the have the model Otrexup into growth shifted targets prove without Supply impact. commercial was digital Our able transition efficacy had our second new brand in model. to XXXX. for and the were XXXX of constraints the pressures we competitive
not third last start the done this priority by The provides month priority to concentration INDOCIN. we're was means. a in good Sympazan but acquisition Our on any reduce of
We FDA the at have meeting a days is which a to within INDOCIN new have aimed and That opportunity the clinical expanding shortly label in the all position expected a begin to Fourth of early program XXXX. a for Thanksgiving. We'll to and life from should file us them INDOCIN. IND was of management an after put pre-IND requesting in far will for go. begin a with be execution matter more feedback cycle
now difficult goal that points they time this we Our year. final XXX higher imagined to our became nearly cost than priority are of than far and This was last more rates sheet basis were our improve reduce balance capital.
to maturity our trailing has months have the that refinancing XXXX back up to of We've a cash debt M&A refinancing a sheet for net on average recorded interest continues XXXX, margins gross this in executed and ended XX our was think We We'll an acquire million, for cash cuts we of in the resources M&A as environment exemplifies. more and friendly corporate However, new asset and to to the this including flow for The profit XX, amount the to cost frees Aquestive cash that patent. robust pushes transaction soon very September environment the our substantial in especially September is milestone able development. timely $X.X transaction business $XX that portfolio. which buyer We're close and products and environment protection asset the to growing. very acquired patent the half now sales. quarter have X.Xx right Sympazan for now trailing this add ripen balance revenues. million to is we In
and In third X and INDOCIN addition, were. than Last us had contract strategies diligence implemented enhanced much without strategies we've for time. commercial quarter external we at a the built as more for internal would be these our help in what discussed resources transaction specifics quarter, identify hired that to resources to
Assertio from in the XXXB. to drug includes Medicaid withdraw action rebate Participation which these government taken is voluntary. programs has program
our net million of growth to to XXXB see annual expect By significant losses significant profit. $X the As our the immediate we million a annually. in revenue result $X incurring inside and we exiting, saw program, of in of products we were an summed that the utilization increase
described expect Paul in low which of by was in from exit, reversal fourth from XXs. in normally quarter. remove reverse accrual had our avoid XXXB Offsetting in in seen our significant for on inventories in under detail. and days an X deliberately under volumes reduced public we were This wanted we products the program Our to further over end onetime this actions channel to quantities of public INDOCIN product what to had made to Since a the negative customers our we is impact quarter expected a that product July. this September which of ahead the revenues notice for returns our
Our available. benefit longer sales price unprofitable estimates is assume million no $X for that cease a this these because
to still conclude, it's there and the upside customers while to acquire early be this. far does exist continue If necessary medically to to However, products for them. find our opportunity too
purchase our Sympazan. we from development well. that offering customers programs to a excited or Assertio at looking as about are search. the for quite directly the to for for We're price of discount We published all the list in business potential criteria It were fits WAC
the received month. milestone that $X the the later payment long-lived Shortly after First, a which be made the this IP. patent have acquisition, triggered million completing for Quest allowance of notice will
be in IP Orange and the the protection during included first patent this quarter of to issued XXXX. book expect 'XX to and We will extend
sales it's annual and Sympazan expect in of $X.X Second, adjusted that million adjusted on basis, the been we from EPS $X.XX generating the million about full had accretive. to market annual million. On accounting dilution EBITDA $X.X add for in between it the and to $X convert.
content sales to in LGS. and a The The competitive $X.X what year-over-year than treatment little which different of it niche in Quest third opportunities complete the a diligence, net a positive reported pressure Otrexup. have the for generates represented aware quarter commonly card there's we in situation of to Many very stable therapy medical liquid in product has has payer Third, the diligence nice growth. it's From environment, million saw very carbohydrate and seizures. of for growth XX%. X% of children physicians of keto put the have. clobazam noticed were few to are just a Sympazan We XX% control the containing that the under of products these on keto that restrictive addition liquid or used formulations their daily more diet limits the diet.
nonpersonal the the to already. to product both and launched XX Fourth, molecule be In addition, physicians are it is now platform, commercial part with We're reps. proud We to message Awareness we XXXX our advocacy prior very had Quest than expand Day XX that nicely acquisition, clobazam familiar into with the opportunity we less where physician of with which our who fits fit the have of and Sympazan are awareness raising also and they excited what November educational territories. model. an this will partner largely filled it epilepsy in community beginning to within strong think LGS. very upon was at LGS reach our awareness. X the is very in can this epilepsy month. And community marked with patient treating
In was it terms our our goal of on the business, help, diversify further Sympazan to while does side. smaller mathematically
while As seeing mentioned, had the larger and M&A smaller-sized were being accelerate, pipeline are ones delayed. acquisitions we our the we
are a OTREXUP gross $X way are goal. We million of acquiring goal over had approximate of to We $XX million X/X that $XX from larger an accomplishing transactions. million transformative originally profit us set those now by XXXX. we The additional Sympazan, products from a and in brought the still little pursuing that
to year M&A I'm so another goal. this we a a pipeline, environment the go, to have capabilities We multitask, deep favorable and can confident accomplish
we're XXXX the are to submission very investment FDA. expecting our close in Finally, NES. for able still NDA They pivotal for that finish to year the to their being is
to As or equity We decide not acceptance NDA. accepted the a to until reminder, our to has is update of the FDA XX up known accept. FDA not it expect has filing. or provide whether the investment whether to do converts upon The investors FDA to not any to days
discuss our turn the Paul? Paul I'll Now, to to call over quarterly results.
